CANF

Can-Fite BioPharma Ltd.

Phase 3 AI-extracted

Namodenoson

hepatocellular carcinoma

Resolved

7days ago

Phase 3 readout · Jun 30, 2026

What's at stake Phase 3 trial results for Namodenoson in hepatocellular carcinoma are due Jun 30, 2026. A clean hit validates the program; a miss can gap the stock down hard.

Primary source · SEC 6-K verified 12h ago

“The publication reports that namodenoson significantly inhibited adipocyte proliferation and lipid droplet accumulation in a dose-dependent manner.”

Add to calendar Post on X Reddit

Provenance